Kent Kresa to Retire From MannKind's Board of Directors; Steven B. Binder to Be Appointed to the Board
Kent Kresa to Retire From MannKind's Board of Directors; Steven B. Binder to Be Appointed to the Board
"We are sincerely grateful for two decades of invaluable leadership that Kent has provided the Board of Directors," said James S. Shannon, Chairman of the Board. "We are looking forward to Steve joining the Board as he was instrumental in providing financial stewardship to MannKind during his tenure and helped bring MannKind into its current era with multiple revenue streams and healthy pipeline progression."DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Kent Kresa has decided to retire from MannKind's Board of Directors effective September 30, 2024. In addition, the Board of Directors has appointed Steven B. Binder to the Board, also effective September 30, 2024.
2024年8月14日，康涅狄格州丹伯里和加利福尼亚州WESTLAKE VILLAGE，曼恩凯德生物医疗公司（纳斯达克股票代码：MNKD）宣布，该公司专注于开发和商业化用于治疗内分泌和孤儿肺病患者的创新吸入疗法产品和设备，并于2024年9月30日起，Kent Kresa决定从曼恩凯德的董事会中退休。此外，董事会已于同日任命Steven b. Binder加入董事会。
Kresa, who has served on MannKind's Board of Directors since June 2004, was Chairman from 2016 until December 2020. Upon his retirement from the MannKind Board, Mr. Kresa will continue to be associated with the company in the capacity of Chairman Emeritus.
Kresa自2004年6月以来一直担任MannKind董事会成员，并于2016年至2020年12月担任主席。在退出曼恩凯德董事会后，Kresa先生将继续担任公司董事长荣誉职务。
Binder previously served as MannKind's Chief Financial Officer from July 2017 until April 2024 and currently serves as Executive Vice President, Special Projects. Mr. Binder will remain in that role until he joins the Board of Directors on September 30, 2024, after which he will no longer be an employee of the Company.
Binder曾于2017年7月至2024年4月担任曼恩凯德首席财务官，目前担任执行副总裁、特殊项目。Binder先生将保持这一职位，直到在2024年9月30日加入董事会后，他将不再担任公司员工。
"We are sincerely grateful for two decades of invaluable leadership that Kent has provided the Board of Directors," said James S. Shannon, Chairman of the Board. "We are looking forward to Steve joining the Board as he was instrumental in providing financial stewardship to MannKind during his tenure and helped bring MannKind into its current era with multiple revenue streams and healthy pipeline progression."
曼恩凯德董事会主席詹姆斯·S·香农说：“我们对Kent过去二十年为董事会提供的宝贵领导力真诚感激。我们期待Steve的加入，他在担任财务长期间为曼恩凯德提供了重要的财务管理，并帮助曼恩凯德进入了目前拥有多个营业收入来源和健康的管道发展的时代。”
With the addition of Binder, there will remain nine total members of the MannKind Board of Directors.
加入Binder后，曼恩凯德董事会成员总数将保持为9人。
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
曼恩凯德生物医疗公司（Nasdaq：MNKD）专注于为那些患有内分泌和孤儿肺病的患者开发和商业化创新吸入治疗产品和设备。
我们致力于利用我们的配方能力和设备工程的技术，减轻糖尿病，非结核分枝杆菌（NTM）肺病，肺纤维化和肺动脉高压等疾病的负担。我们的标志性技术——干粉配方和吸入设备——可以快速，方便地向肺的深处输送药物，从而在目标疾病的治疗方面产生局部或进入系统循环的作用，具体取决于治疗目标。
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
我们致力于利用我们的配方能力和设备工程专业知识减轻糖尿病、非结核分枝杆菌（NTM）肺病、肺纤维化和肺动脉高压等疾病的负担。我们的标志性技术——干粉制剂和吸入设备——为药物快速、便捷地输送到深层肺部提供了可能，这些药物可以在当地发挥功效，也可以进入系统循环，具体取决于治疗指示。
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
在曼恩凯德生物医疗的全国性合作团队的热情协作下，我们的使命是让人们掌控自己的健康和自由生活。
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
请访问mannkindcorp.com获取更多信息，并在LinkedIn、Facebook、X或Instagram上关注我们。
MANNKIND is a registered trademark of MannKind Corporation.
曼恩凯德生物医疗是曼恩凯德的已注册商标。
For MannKind:
Christie Iacangelo
Corporate Communications
(818) 292-3500
Email: media@mnkd.com
Investor Relations
(818) 661-5000
Email: ir@mnkd.com
对于曼恩凯德生物医疗:
电子邮件：media@mnkd.com
企业通讯
（818）292-3500
电子邮件：ir@mnkd.com
投资者关系
(818) 661-5000
电子邮件：ir@mnkd.com
Source: MannKind
来源：曼恩凯德生物医疗
